Detalles de la búsqueda
1.
Durability of no evidence of disease activity-3 (NEDA-3) in patients receiving cladribine tablets: The CLARITY extension study.
Mult Scler
; 28(8): 1219-1228, 2022 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-34634968
2.
Evolution from a first clinical demyelinating event to multiple sclerosis in the REFLEX trial: Regional susceptibility in the conversion to multiple sclerosis at disease onset and its amenability to subcutaneous interferon beta-1a.
Eur J Neurol
; 29(7): 2024-2035, 2022 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-35274413
3.
Real-world effectiveness of cladribine for Australian patients with multiple sclerosis: An MSBase registry substudy.
Mult Scler
; 27(3): 465-474, 2021 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-32530363
4.
Efficacy of subcutaneous interferon ß-1a on MRI outcomes in a randomised controlled trial of patients with clinically isolated syndromes.
J Neurol Neurosurg Psychiatry
; 85(6): 647-53, 2014 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-24292999
5.
Preferences and Perspectives of Specialist Multiple Sclerosis Nurses and Patients with Multiple Sclerosis Regarding the New RebiSmart® 3.0 Autoinjector versus Other Assistive Devices.
Med Devices (Auckl)
; 17: 59-71, 2024.
Artículo
en Inglés
| MEDLINE | ID: mdl-38404632
6.
Evolution of the RebiSmart® Electromechanical Autoinjector to Improve Usability in Support of Adherence to Subcutaneous Interferon Beta-1a Therapy for People Living with Multiple Sclerosis.
Patient Prefer Adherence
; 17: 1923-1933, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-37581193
7.
Assessment of adherence to, and persistence with, an electromechanical autoinjector for subcutaneous interferon beta-1a injections for multiple sclerosis treatment over 3 years.
Expert Opin Drug Deliv
; 20(6): 863-870, 2023 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-37273189
8.
The spatio-temporal relationship between concurrent lesion and brain atrophy changes in early multiple sclerosis: A post-hoc analysis of the REFLEXION study.
Neuroimage Clin
; 38: 103397, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-37086648
9.
Family planning in people with multiple sclerosis: a plain language summary.
Neurodegener Dis Manag
; 12(1): 9-14, 2022 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-35112573
10.
Disease stability over five years in people with multiple sclerosis treated with cladribine tablets: a plain language summary.
Neurodegener Dis Manag
; 12(6): 295-301, 2022 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-36017780
11.
The effect of cladribine tablets in people with more active multiple sclerosis: a plain language summary.
Neurodegener Dis Manag
; 12(6): 285-293, 2022 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-35920065
12.
Side effects that occurred early in people with multiple sclerosis during the first year of treatment with cladribine tablets: a plain language summary.
Neurodegener Dis Manag
; 12(1): 1-7, 2022 02 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-35019731
13.
The spatio-temporal relationship between white matter lesion volume changes and brain atrophy in clinically isolated syndrome and early multiple sclerosis.
Neuroimage Clin
; 36: 103220, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-36274376
14.
COVID-19 in patients with multiple sclerosis treated with cladribine tablets: An update.
Mult Scler Relat Disord
; 51: 102929, 2021 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-33813097
15.
Family Planning Decision Making in People With Multiple Sclerosis.
Front Neurol
; 12: 620772, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-33995240
16.
Outcomes of COVID-19 among patients treated with subcutaneous interferon beta-1a for multiple sclerosis.
Mult Scler Relat Disord
; 56: 103283, 2021 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-34619487
17.
Acting centrally or peripherally: A renewed interest in the central nervous system penetration of disease-modifying drugs in multiple sclerosis.
Mult Scler Relat Disord
; 56: 103264, 2021 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-34547609
18.
Efficacy of cladribine tablets in high disease activity patients with relapsing multiple sclerosis: post hoc analysis of subgroups with and without prior disease-modifying drug treatment.
Curr Med Res Opin
; 37(3): 459-464, 2021 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-33331183
19.
Treatment-emergent adverse events occurring early in the treatment course of cladribine tablets in two phase 3 trials in multiple sclerosis.
Mult Scler J Exp Transl Clin
; 7(3): 20552173211024298, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-34345436
20.
Long-Term Disease Stability Assessed by the Expanded Disability Status Scale in Patients Treated with Cladribine Tablets 3.5 mg/kg for Relapsing Multiple Sclerosis: An Exploratory Post Hoc Analysis of the CLARITY and CLARITY Extension Studies.
Adv Ther
; 38(9): 4975-4985, 2021 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-34370275